As a valued subscriber to the wealth of resources published by Relias Media, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
In a large, randomized, double-blind, multicenter clinical trial, researchers found that isavuconazole did not meet the primary endpoint of noninferiority compared to caspofungin for candidemia and invasive candidiasis.
Pyuria is common in asymptomatic children with neurogenic bladders, especially after bladder surgery. The simple presence of pyuria does not necessarily indicate a need for antibiotic treatment.
Enhancing the immune response with checkpoint inhibitors may be beneficial in the management of progressive multifocal leukoencephalopathy, a viral disease previously recalcitrant to therapy.
A before-and-after intervention study compared 170 patients treated with either oxacillin IV or vancomycin IV for six weeks (plus gentamicin IV given during the first five days) to 171 patients who were treated with TMP/SMZ IV plus clindamycin IV for the first week followed by TMP/SMZ PO (without clindamycin) to complete a six-week course. Mortality and hospital length of stay were significantly less in the TMP/SMZ-treated patients.
Help us deliver the content important to you! Take five minutes to complete our annual user survey and be entered to win a yearlong subscription to Relias Media's entire newsletter catalog
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, is a consultant for Genomic Health Reference Laboratory, Siemens Clinical
Laboratory, and CareDx Clinical Laboratory. Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Updates Author
Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jonathan Springston, and
Editorial Group Manager Leslie Coplin report no financial relationships to this field of study.
